The Effect of a Comprehensive Rehabilitation Program Using Robotic Walking and Functional Electrical Stimulation Technologies on Balance and Walking in Children With Cerebral Palsy - Trial NCT06403891
Access comprehensive clinical trial information for NCT06403891 through Pure Global AI's free database. This phase not specified trial is sponsored by Ankara City Hospital Bilkent and is currently Recruiting. The study focuses on Cerebral Palsy. Target enrollment is 30 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Observational
Sponsor & Location
Ankara City Hospital Bilkent
Timeline & Enrollment
N/A
Mar 15, 2022
May 15, 2024
Primary Outcome
Cadence,Step length,Stride length,Track width,Range of motion of joints during the gait cycle,Range of motion of the pelvis in the frontal plane during the gait cycle,Plantar surface pressure distribution
Summary
The aim of this study was to investigate the effect of a comprehensive rehabilitation program
 using robotic walking and functional electrical stimulation technologies on balance and gait
 in children with cerebral palsy. This study was planned as a prospective observational study.
 A total of 30 patients in two groups were planned to be included in the study. Patients in
 both groups were planned to receive a 6-week conventional rehabilitation program that was
 prepared to meet the requirements of their clinical conditions, including neurophysiological
 exercises, balance-coordination and posture exercises. The case group was planned to consist
 of patients who received a comprehensive rehabilitation program using high-tech devices
 including functional electrical stimulation (FES) and robotic rehabilitation applications in
 addition to the conventional rehabilitation program.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06403891
Non-Device Trial